TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
SIGA Technologies Inc. (SIGA)
US:NASDAQ Investor Relations:
investor.siga.com/investor-relations
Company Research
Source: GlobeNewswire
Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor to supply TEPOXX to Japan’s national stockpileComprehensive data package demonstrates strong safety profile and robust preclinical efficacy NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, a commercial stage pharmaceutical company, announced today that its antiviral treatment TEPOXX (tecovirimat 200 mg capsules), marketed as TPOXX in the United States, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg. TEPOXX is the first antiviral therapy approved by the Pharmaceuticals and Medical Devices Agency (PMDA), in collaboration with the Japan Ministry of Health, Labour and Welfare, for the treatment of orthopoxviruses.
Show less
Read more
Impact Snapshot
Event Time:
SIGA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SIGA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SIGA alerts
High impacting SIGA Technologies Inc. news events
Weekly update
A roundup of the hottest topics
SIGA
News
- TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses [Yahoo! Finance]Yahoo! Finance
- Are Investors Undervaluing Siga Technologies (SIGA) Right Now? [Yahoo! Finance]Yahoo! Finance
- Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced [Yahoo! Finance]Yahoo! Finance
- Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox AnnouncedGlobeNewswire
SIGA
Sec Filings
- 12/13/24 - Form 8-K
- 12/10/24 - Form 8-K
- 11/8/24 - Form SC
- SIGA's page on the SEC website